GVS S.p.A. (GVS) Earnings Call Transcripts

GVS S.p.A.'s Latest Earnings Call - March 26, 2026

GVS S.p.A. reported its full-year 2025 results, showing a modest revenue increase of 2% to EUR 425 million, excluding FX impacts. Adjusted EBITDA rose by 3% to EUR 107 million, with a margin improvement to 25.2%. Adjusted net income increased by 5.9% to EUR 47.4 million. The company provided guidance for low single-digit revenue growth in 2026, excluding FX, with an expected EBITDA margin improvement of 20 to 50 basis points. The stock could be influenced by the company's ability to manage FX headwinds and execute on its strategic initiatives in MedTech and Transfusion Medicine.

Reported metrics

Guidance from management

GVS expects low single-digit revenue growth in 2026, excluding FX, with an EBITDA margin improvement of 20 to 50 bps. The leverage ratio is expected to be around 1.8x.

What management said

Basically, we are, let's say, launching all across now the production of TM is all under our control. We are already producing everything in our plants. Of course, we want to monitor this and we see this growing gradually during the year. So that's, let me say, the explanation of this gradual expansion through the year.

Transfusion Medicine, yes plus the MedTech reorganization and then the more focus, et cetera, also this will start to pay back during the year. So these are the reasons why we see this -- we have made this statement.

What analysts pressed on

Analysts expressed concerns about the impact of FX headwinds and the company's ability to manage the decline in the U.S. Dialysis business. There were also questions about the potential impact of geopolitical tensions on raw material costs and the company's pricing strategy.

Main topics on the call

• Revenue Performance — Revenue increased by 2% to EUR 425 million, excluding FX. The Healthcare & Life Sciences division grew by 1.5%, while Energy Mobility declined by 7.5%, and Safety grew by nearly 12%.
• EBITDA and Margin Improvement — Adjusted EBITDA increased by 3% to EUR 107 million, with a margin improvement of 95 bps to 25.2%. Management attributed this to a 1.4% pricing increase.
• FX Impact — The company faced a negative FX impact of EUR 12.5 million, primarily due to the depreciation of the U.S. dollar.
• MedTech and Transfusion Medicine Strategy — GVS plans to establish new subdivisions in MedTech to focus on high-growth niches and accelerate new product development in Transfusion Medicine.

Read the full GVS S.p.A. transcript (March 26, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 6 GVS S.p.A. earnings call transcripts on record, spanning March 25, 2025 to May 14, 2026. Based on this history, GVS S.p.A. reports quarterly. The most recent call on file is dated May 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

GVS

Exchange

BIT

Country

IT

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

6

First call

March 25, 2025

Most recent

May 14, 2026

Reporting cadence

quarterly